Browsing Clinical Studies by author "Hall, Emma"
Now showing items 1-20 of 86
-
The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis.
Cullen, M; Huddart, R; Joffe, J; Gardiner, D; Maynard, L; Hutton, P; Mazhar, D; Shamash, J; Wheater, M; White, J; Goubar, A; Porta, N; Witts, S; Lewis, R; Hall, E; 111 Trial Management Group (2019-12-19)BACKGROUND:Standard management in the UK for high-risk stage 1 nonseminoma germ cell tumours of the testis (NSGCTT) is two cycles of adjuvant bleomycin, etoposide (360 mg/m2), and cisplatin (BE360P) chemotherapy, or ... -
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; McGale, P; Peto, R; Pritchard, KI; Bergh, J; Dowsett, M; Hayes, DF; EBCTCG (2017-11)<h4>Background</h4>The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending ... -
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial
Birtle, A; Johnson, M; Chester, J; Jones, R; Dolling, D; Bryan, RT; Harris, C; Winterbottom, A; Blacker, A; Catto, JWF; Chakraborti, P; Donovan, JL; Elliott, PA; French, A; Jagdev, S; Jenkins, B; Keeley, FX; Kockelbergh, R; Powles, T; Wagstaff, J; Wilson, C; Todd, R; Lewis, R; Hall, E (Elsevier BV, 2020-04) -
Advancing radiotherapy for bladder cancer: Randomised phase II trial of adaptive image guided standard or dose escalated tumour boost radiotherapy (RAIDER)
Hall, E; Hafeez, S; Lewis, R; Huddart, R -
ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer
Nutting, C; Morden, J; Bernstein, D; Beasley, M; Cosgrove, V; Fisher, S; Foran, B; Guerrero-Urbano, T; Gujral, D; Harrington, K; Junor, E; Mehanna, H; Miah, A; Palaniappan, N; Ramkumar, S; Sanghera, P; Sen, M; Sibtain, A; Soe, W; West, C; Piercey, D; Witts, S; Emson, M; Hall, E (ELSEVIER IRELAND LTD, 2017-03-01) -
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).
Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2019-04)<h4>Background</h4>Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy.<h4>Objective</h4>To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, ... -
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Mostafid, AH; Porta, N; Cresswell, J; Griffiths, TRL; Kelly, JD; Penegar, SR; Davenport, K; McGrath, JS; Campain, N; Cooke, P; Masood, S; Knowles, MA; Feber, A; Knight, A; Catto, JWF; Lewis, R; Hall, E (2020-06)<h4>Objectives</h4>To evaluate the activity of intravesical mitomycin-C (MMC) to ablate recurrent low-risk non-muscle-invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention ... -
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Goodall, J; Mateo, J; Yuan, W; Mossop, H; Porta, N; Miranda, S; Perez-Lopez, R; Dolling, D; Robinson, DR; Sandhu, S; Fowler, G; Ebbs, B; Flohr, P; Seed, G; Rodrigues, DN; Boysen, G; Bertan, C; Atkin, M; Clarke, M; Crespo, M; Figueiredo, I; Riisnaes, R; Sumanasuriya, S; Rescigno, P; Zafeiriou, Z; Sharp, A; Tunariu, N; Bianchini, D; Gillman, A; Lord, CJ; Hall, E; Chinnaiyan, AM; Carreira, S; de Bono, JS; TOPARP-A investigators (2017-09)Biomarkers for more precise patient care are needed in metastatic prostate cancer. We have reported a phase II trial (TOPARP-A) of the PARP inhibitor olaparib in metastatic prostate cancer, demonstrating antitumor activity ... -
Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Huddart, RA; Birtle, A; Maynard, L; Beresford, M; Blazeby, J; Donovan, J; Kelly, JD; Kirkbank, T; McLaren, DB; Mead, G; Moynihan, C; Persad, R; Scrase, C; Lewis, R; Hall, E (2017-11)<h4>Objectives</h4>To test the feasibility of a randomised trial in muscle-invasive bladder cancer (MIBC) and compare outcomes in patients who receive neoadjuvant chemotherapy followed by radical cystectomy (RC) or selective ... -
Clinical development of new drug-radiotherapy combinations.
Sharma, RA; Plummer, R; Stock, JK; Greenhalgh, TA; Ataman, O; Kelly, S; Clay, R; Adams, RA; Baird, RD; Billingham, L; Brown, SR; Buckland, S; Bulbeck, H; Chalmers, AJ; Clack, G; Cranston, AN; Damstrup, L; Ferraldeschi, R; Forster, MD; Golec, J; Hagan, RM; Hall, E; Hanauske, A-R; Harrington, KJ; Haswell, T; Hawkins, MA; Illidge, T; Jones, H; Kennedy, AS; McDonald, F; Melcher, T; O'Connor, JPB; Pollard, JR; Saunders, MP; Sebag-Montefiore, D; Smitt, M; Staffurth, J; Stratford, IJ; Wedge, SR; NCRI CTRad Academia-Pharma Joint Working Group (2016-10)In countries with the best cancer outcomes, approximately 60% of patients receive radiotherapy as part of their treatment, which is one of the most cost-effective cancer treatments. Notably, around 40% of cancer cures ... -
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer.
Huddart, R; Hafeez, S; Lewis, R; McNair, H; Syndikus, I; Henry, A; Staffurth, J; Dewan, M; Vassallo-Bonner, C; Moinuddin, SA; Birtle, A; Horan, G; Rimmer, Y; Venkitaraman, R; Khoo, V; Mitra, A; Hughes, S; Gibbs, S; Kapur, G; Baker, A; Hansen, VN; Patel, E; Hall, E; HYBRID Investigators (2020-12-11)<h4>Purpose</h4>Hypofractionated radiation therapy can be used to treat patients with muscle-invasive bladder cancer unable to have radical therapy. Toxicity is a key concern, but adaptive plan-of the day (POD) image-guided ... -
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
Ahmed, M; Dorling, L; Kerns, S; Fachal, L; Elliott, R; Partliament, M; Rosenstein, BS; Vega, A; Gómez-Caamaño, A; Barnett, G; Dearnaley, DP; Hall, E; Sydes, M; Burnet, N; Pharoah, PDP; Eeles, R; West, CML (2016-05)<h4>Background</h4>Numerous germline single-nucleotide polymorphisms increase susceptibility to prostate cancer, some lying near genes involved in cellular radiation response. This study investigated whether prostate cancer ... -
Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001).
Hall, E; Cameron, D; Waters, R; Barrett-Lee, P; Ellis, P; Russell, S; Bliss, JM; Hopwood, P; TACT Trial Investigators (2014-09)<h4>Background</h4>The TACT trial (CRUK/01/001) compared adjuvant sequential FEC-docetaxel (FEC-D) chemotherapy with standard anthracycline-based chemotherapy of similar duration in women with early breast cancer. Results ... -
Contribution of Common SNPs to Variability in Late Radiation Therapy Toxicity in Prostate Cancer
Kerns, S; Hao, K; Stahl, E; Rosenstein, BS; CaamaNo, AG; Carballo, A; Peleteiro, P; Fachal, L; Vega, A; Dunning, A; Sydes, M; Hall, E; Dearnaley, D; West, CML; Ostrer, H (ELSEVIER SCIENCE INC, 2017-10-01) -
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley, D; Syndikus, I; Mossop, H; Khoo, V; Birtle, A; Bloomfield, D; Graham, J; Kirkbride, P; Logue, J; Malik, Z; Money-Kyrle, J; O'Sullivan, JM; Panades, M; Parker, C; Patterson, H; Scrase, C; Staffurth, J; Stockdale, A; Tremlett, J; Bidmead, M; Mayles, H; Naismith, O; South, C; Gao, A; Cruickshank, C; Hassan, S; Pugh, J; Griffin, C; Hall, E; CHHiP Investigators (2016-08)<h4>Background</h4>Prostate cancer might have high radiation-fraction sensitivity that would give a therapeutic advantage to hypofractionated treatment. We present a pre-planned analysis of the efficacy and side-effects ... -
Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians’ Practices across Six Randomised Controlled Trials
Rooshenas, L; Elliott, D; Wade, J; Jepson, M; Paramasivan, S; Strong, S; Wilson, C; Beard, D; Blazeby, JM; Birtle, A; Halliday, A; Rogers, CA; Stein, R; Donovan, JL (2016-10-18) -
COSTAR trial results: 3-D Conformal Radiotherapy vs Cochlea-Sparing IMRT in parotid cancer patients
Nutting, C; Morden, J; Beasley, M; Bhide, S; Emson, M; Evans, M; Fresco, L; Gujral, D; Harrington, K; Lemon, C; Neupane, R; Newbold, K; Prestwich, R; Robinson, M; Sanghera, P; Sivaramalingam, M; Sydenham, M; Wells, E; Witts, S; Hall, E (ELSEVIER IRELAND LTD, 2017-03-01) -
DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer.
Petkar, I; Rooney, K; Roe, JWG; Patterson, JM; Bernstein, D; Tyler, JM; Emson, MA; Morden, JP; Mertens, K; Miles, E; Beasley, M; Roques, T; Bhide, SA; Newbold, KL; Harrington, KJ; Hall, E; Nutting, CM (2016-10-06)<h4>Background</h4>Persistent dysphagia following primary chemoradiation (CRT) for head and neck cancers can have a devastating impact on patients' quality of life. Single arm studies have shown that the dosimetric sparing ... -
Derivation of dose/volume constraints for the anorectum from clinician and patient-reported outcomes in the CHHiP trial of radiotherapy fractionation.
Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; Dearnaley, D; Gulliford, S; CHHiP Trial Management Group (2020-01-24)BACKGROUND:The CHHiP trial randomised 3216 men with localised prostate cancer (1:1:1) to three radiotherapy fractionation schedules: 74Gy/37 fractions (f) over 7.4 weeks, 60Gy/20f/4 weeks and 57Gy/19f/3.8 weeks. Literature-based ... -
Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
Perez-Lopez, R; Mateo, J; Mossop, H; Blackledge, MD; Collins, DJ; Rata, M; Morgan, VA; Macdonald, A; Sandhu, S; Lorente, D; Rescigno, P; Zafeiriou, Z; Bianchini, D; Porta, N; Hall, E; Leach, MO; de Bono, JS; Koh, D-M; Tunariu, N (2017-04)Purpose To determine the usefulness of whole-body diffusion-weighted imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials ...